NEW YORK (360Dx) – Beckman Coulter today announced it has filed a 510(k) application with the US Food and Drug Administration for clearance of its Early Sepsis Indicator.

The hematology-based solution is intended to provide clinicians information about sepsis and the risk of developing sepsis in patients in acute care settings. It is offered as part of a standard complete blood count with differential test, Beckman Coulter said, adding results can be achieved in less than one hour without additional workflow burden for clinicians or clinical labs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.